Sigma Planning Corp Decreases Holdings in Johnson & Johnson $JNJ

Sigma Planning Corp trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 6.0% in the second quarter, HoldingsChannel reports. The fund owned 55,677 shares of the company’s stock after selling 3,559 shares during the period. Sigma Planning Corp’s holdings in Johnson & Johnson were worth $8,505,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Greenup Street Wealth Management LLC grew its stake in shares of Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after buying an additional 60 shares during the last quarter. Ellis Investment Partners LLC grew its position in Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after acquiring an additional 62 shares during the last quarter. Cypress Wealth Services LLC increased its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after purchasing an additional 62 shares during the period. Horizon Bancorp Inc. IN lifted its position in Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after purchasing an additional 64 shares during the last quarter. Finally, Global Strategic Investment Solutions LLC boosted its stake in shares of Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after purchasing an additional 65 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on JNJ shares. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Bank of America upped their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $189.02 on Monday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The stock has a market capitalization of $455.40 billion, a P/E ratio of 18.25, a P/E/G ratio of 2.19 and a beta of 0.40. The company’s 50-day moving average is $183.28 and its 200 day moving average is $167.75. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.